Watch the video and download the slides


Highlights of 2020 in prostate, urothelial and kidney cancer

 

Dr Ray Manneh Kopp takes a look at the highlights of 2020 from GU CONNECT, in particular the new trials and practice changing developments in prostate, urothelial and kidney cancer, as well as the impact of COVID-19 on existing treatments and protocols.


Watch the video and download the slides.

Hello, I’m Dr Ray Manneh. I’m a medical oncologist from Colombia, and I’m here to present the highlights of 2020 from GU CONNECT.

 

Although in virtual mode, 2020 has brought numerous news and practice-changing trials. I’ll do a quick review about prostate, urothelial and kidney cancer, but before that I’ll do a quick review about the COVID-19 pandemic recommendations in GU tumours.

 

COVID-19 Recommendations

 

First, for patients we are treating with a curative intent, we should be more keen to use G-CSF and prophylactic antibiotics, trying to avoid hospitalisations. We should try to avoid immunosuppressive agents or steroids – for patients with metastatic prostate cancer, the ADT needs to be started immediately. This ADT can be delayed when patients are on new hormonal therapies, especially abiraterone and we should prefer the new hormonal agents, instead of chemotherapy, whenever it’s possible. For the agents, reducing the skeletal-related events, they may be better postponed. In metastatic kidney cancer with an IMDC of intermediate and poor risk, we should establish the first-line therapy as soon as possible.

 

Prostate Cancer Update

 

Now, talking about the data, the news from prostate cancer, we have three approvals from the FDA – two PARP inhibitors were approved, rucaparib and olaparib. And remember that the PROfound trial this year showed an advantage, in terms of overall survival, in the pre-treated castration-resistant prostate cancer setting, with HRR alterations. The other approval was for PSMA PET-imaging, that is now available in the United States.

 

The era of targeted therapy in prostate cancer is here, and the IPATential 150 trial evaluated ipatasertib, that is an oral AKT inhibitor, that was combined with abiraterone and compared with abiraterone alone for the first-line setting in metastatic castration-resistant prostate cancer.

 

We saw an impact in terms of progression-free survival. This impact is more notable in the PTEN loss population that accounts for around 50% of these patients so we have a biological rationale, an active drug and interesting clinical data.

 

Other interesting data from prostate cancer came from the SPARTAN, ARAMIS and PROSPER trials. We finally saw an advantage in terms of overall survival in the non-metastatic castration-resistant prostate cancer setting so this reinforces our current clinical practice.

 

Bladder Cancer Update

 

Now moving on to urothelial carcinoma, the main news came from ASCO last year at the plenary session which presented the results of the JAVELIN Bladder 100 trial.

 

That is a trial that evaluated avelumab as a maintenance strategy versus best supportive care after first-line platinum-based standard chemotherapy. We saw an advantage in terms of overall survival with a median overall survival of 21.4 months for the avelumab group. So we have a new standard of care – avelumab as a maintenance therapy after chemotherapy when patients get a stable disease or response.

 

Kidney Cancer Update

 

Now moving onto kidney cancer, a quick review. The main news came from ESMO last year. There were presented the CheckMate 9ER trial. The trial tested cabozantinib plus nivolumab vs. sunitinib. We saw a clear impact in terms of progression-free survival and overall survival. The progression-free survival was the primary endpoint, we had a hazard ratio of 0.51. The main point I’d like to tell you about this trial is that we have a really low rate of primary progressors with this combination, so it will be interesting to have this combination in the clinical practice and we hope for new combinations in 2021.

 

So that’s a quick review of the highlights of 2020 on behalf of GU CONNECT, you can get more information at guconnect.cor2ed.com. Thank you very much.

Scientific director at Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia. Chief of Genitourinary Unit and Clinical Research Unit. Medical Oncologist at Clínica Portoazul, Barranquilla, Colombia. I completed medical school at Universidad del Norte, Barranquilla Colombia.  Medical oncologist from University Hospital 12 de Octubre in Madrid, Genitourinary Fellow in the GU unit at  University Hospital 12 de Octubre. Master in molecular oncology from Centro de estudios biosanitarios, CNIIO, ESO. Founder of Grupo de Oncología Genitourinaria de Colombia.  Member of SEOM, ACHO and LACOG-GU. I focus my practice on patients with prostate, bladder, kidney and testicular cancer. 

Dr Ray Manneh Kopp has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, AstraZeneca, BMS, Dr Reddys, Roche, Janssen, Lilly, MSD, Novartis and Technofarma.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Medical Grants from Bayer, AstraZeneca and Eisai Europe Limited.

Meet the experts

Other programmes of interest

Breast-Cancer-Connect-ER-HER2-low-thumbnail-BR2310 Tweetorial
Oncology 
Tweetorial video: Treating ER+/HER2-low metastatic breast cancer, 2L and beyond

Journey through a patient case from testing and diagnosis to treatment and AE management

Experts
Dr Aditya Bardia
Endorsed by
GRASP
  • clock 11 MIN
  • calendar Apr 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
NSCLC-perseverance-pays-off- thumbnail-PO2305 Podcast
Oncology 
Perseverance in molecular testing in NSCLC pays off

Looking beyond the obvious mutations in non-small-cell lung cancer

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
Conference update
Oncology 
ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer

Experts
Prof. Valentina Guarneri, Prof. Matteo Lambertini, Prof. Federico Rojo
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline.
Podcast
Oncology 
mCRC: Optimising patient outcomes with late-line treatment

Maximising outcomes for patients with advanced CRC

Experts
Assoc. Prof. Gerald Prager, Dr Victor Hugo Fonseca de Jesus
Endorsed by
Digestive Cancers Europe 5th anniversary
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Interactive patient case
Oncology 
TRK fusion-positive lung cancer: Diagnosis and treatment

Make decisions for your patient at two key stages in their journey

Experts
Prof. Fernando López-Ríos, Prof. Mark Socinski
  • clock 60 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
Lung cancer expert panel Conference update
Oncology 
ESMO 2023: Lung cancer update

Experts discuss new lung cancer data at a meeting hosted by eChinaHealth and COR2ED

  • clock 43 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from This educational programme is supported by an Independent Medical Education Grant from SystImmune and BeiGene Europe.